Management of Worsening Ascites After Chemotherapy

Initial Diagnostic Approach

Diagnostic paracentesis is mandatory in all patients with worsening ascites to determine the cause, as this is critical to distinguish between malignant ascites progression, cirrhotic decompensation, or treatment-related complications, according to the American Association for the Study of Liver Diseases 1
The workup should include ascitic fluid cell count and differential to rule out spontaneous bacterial peritonitis, as recommended by the American Association for the Study of Liver Diseases 1
Serum-ascites albumin gradient (SAAG) should be measured to differentiate portal hypertension (SAAG ≥1.1 g/dL) from peritoneal carcinomatosis (SAAG <1.1 g/dL), as suggested by the American Association for the Study of Liver Diseases 1
Ascitic fluid total protein and albumin should be assessed for comprehensive evaluation, as recommended by the American Association for the Study of Liver Diseases 1
Bacterial culture in blood culture bottles inoculated at bedside should be performed if infection is suspected, according to the American Association for the Study of Liver Diseases 1

For malignant ascites, the indication for chemotherapy must be carefully reconsidered based on the patient's performance status, as most clinical trials exclude patients with severe peritoneal metastases and massive ascites, as stated by the European Society for Medical Oncology 2
Infusional 5-fluorouracil (5FUci) is the preferred first-line option for patients with adequate performance status, as it demonstrated the ability to restore oral intake in 41% of patients with bowel obstruction and has a favorable toxicity profile, according to the European Society for Medical Oncology 2
Weekly paclitaxel is an alternative that improved ascites volume in 39% of patients and showed better tolerability than other regimens, as suggested by the European Society for Medical Oncology 2
For portal hypertension-related ascites, first-line treatment consists of sodium restriction to 88 mmol/day (2000 mg/day or 5g salt/day) and spironolactone 100 mg daily as initial diuretic, as recommended by the American Association for the Study of Liver Diseases 3
Furosemide 40 mg daily should be added if needed, maintaining a 100:40 mg ratio, according to the American Association for the Study of Liver Diseases 4

Serum electrolytes, creatinine, and weight should be checked within 1 week of diuretic initiation or dose changes, as recommended by the American Association for the Study of Liver Diseases 4
Hyponatremia management should involve fluid restriction only if serum sodium <120-125 mmol/L, as suggested by the European Association for the Study of the Liver 6

NSAIDs should be avoided completely, as they reduce diuretic efficacy, cause sodium retention, and can convert diuretic-sensitive ascites to refractory ascites, according to the American Association for the Study of Liver Diseases 3
Fluids should not be restricted routinely, as this is only indicated for severe hyponatremia (<120-125 mmol/L) and may worsen effective hypovolemia, as recommended by the European Association for the Study of the Liver 6
Intravenous diuretics should be avoided, as oral administration is standard and IV use can cause acute kidney injury from rapid fluid shifts, according to the American Association for the Study of Liver Diseases 7

Serial therapeutic paracenteses every 2-3 weeks with albumin replacement should be considered if ascites persists despite maximum diuretic doses and sodium restriction, as recommended by the American Association for the Study of Liver Diseases 3
TIPS should be considered only in highly selected cirrhotic patients without contraindications, according to the American Association for the Study of Liver Diseases 3
TIPS is contraindicated in malignant ascites and Fontan-type circulation, as stated by the European Association for the Study of the Liver 8